Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT04462406 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

NETWORK

Sponsor class

Conditions

Advanced Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Melanoma AJCC v8
Unresectable Acral Lentiginous Melanoma
Unresectable Melanoma
Unresectable Mucosal Melanoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
OTHER: Patient Observation
BIOLOGICAL: Pembrolizumab

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]